Akso Health vs Mangoceuticals
Akso Health is the larger business, with $13.8m of revenue in fiscal 2026 against $456,021 for Mangoceuticals (30.3 times as much). Akso Health grew faster (-6.4% against -26.0%). Akso Health kept more of each dollar of sales as profit: a net margin of -135.0% against -4526.8%.
| Latest fiscal year | Akso HealthAHG, 2026 | MangoceuticalsMGRX, 2025 |
|---|---|---|
| Revenue | $13.8m | $456,021 |
| Revenue growth | -6.4% | -26.0% |
| Net income | −$18.7m | −$20.6m |
| Operating margin | — | -3954.3% |
| Net margin | -135.0% | -4526.8% |
| Return on equity | -9.8% | -141.6% |
| Free cash flow | −$12.8m | −$5.9m |
| Cash | $170,572 | $1.5m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $860m | $3.6m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 4 sales |